Cytomegalovirus (CMV) causes an infection, which is followed by a lifelong latency. CMV has received much attention in clinical studies, but little is known about the genetic basis of this common infection. To identify genetic polymorphisms associated with the susceptibility to and strength of anti-CMV immunoglobulin G (IgG) response to CMV infection, we conducted a genome-wide association study (GWAS) using an Illumina BeadChip containing 670 000 probes and participants from the Cardiovascular Risk in Young Finns Study, including 1486 anti-CMV IgG seropositive and 648 seronegative individuals. Statistical analyses were performed using logistic (for susceptibility) and linear regression (for strength of antibody response). None of single-nucleotide polymorphisms (SNPs) was found to be associated with susceptibility to CMV infection at the level of genome-wide significance (Po5 Â 10
Introduction
Cytomegalovirus (CMV) is an easily transmissible beta herpesvirus with a reported seroprevalence of 30-90% in industrialized countries. 1 After a primary infection, which is usually asymptomatic, the virus remains within the individual in a latent form and periodically reactivates. Infection occurs in a variety of cell types, including monocytes/macrophages, endothelial cells, epithelial cells and fibroblasts. [2] [3] [4] [5] Macrophages and endothelial cells have been implicated as the sites of CMV persistence and latency. 6 In immunocompetent individuals, the virus rarely causes clinical problems, but in situations involving immunosuppression, CMV reactivation can cause an array of damaging clinical effects. CMV has been linked with well-known clinical disorders including cancer, 7 cardiovascular disease 8, 9 and functional impairment in the elderly. 10 CMV has been proposed as a driving force in immunosenescence. 11, 12 In infected individuals, CMV interferes with the normal functioning of the immune system in many ways. It changes the function of infected cells and alters gene expression. The anti-CMV response is associated with both T-and B-cells, but there is evidence that the innate immune system has an important role in defending against infection and also in priming the adaptive immune response. The stimulation of Toll-like receptors by CMV is known to activate signal pathways that induce the expression of inflammatory cytokines that awake innate immune system and assist with the upregulation of molecules important for the activation of adaptive immunity. 13, 14 It has been reported that antiviral genes, including the interferon-stimulated gene family genes, and inflammatory genes, including interleukin 6 (IL-6), IL-7, IL-11, regulated on activation, normal T-cell expressed and secreted (RANTES), tumor necrosis factor-a (TNF-a) and cyclooxygenase 2 (COX-2), were all induced in CMV-infected fibroblast. [15] [16] [17] [18] In the adaptive immunity, both humoral and T-cell-mediated immune responses can be observed. The humoral response acts to restrict viral dissemination and acts to limit the severity of the disease. 19, 20 The T-cell-mediated immune response is the predominant mechanism by which CMV replication is controlled, but also natural killer cells might have a role. 1 The role of host genetic factors associated with the CMV infection has not been extensively studied, but some candidate genes have been associated with human susceptibility to members of the Herpesviridae family, including CMV. 21, 22 Also polymorphisms in genes associated with inflammatory signalling, including IL-10/IL-10R, have been found to be associated with herpesviruses. 23, 24 Using murine models, several studies have identified host genetic polymorphisms associated with susceptibility to murine CMV. 25 To obtain more information about the mechanisms of susceptibility to and the strength of anti-CMV immunoglobulin G (IgG) antibody response to CMV infection, we have performed a genome-wide association analysis (GWAS) in a healthy adult population, using serum anti-CMV IgG titer to detect infection.
Results
Characteristics of the CMV-seropositive and -seronegative participant are shown in Table 1 . The majority of the represented variables did not differ between seropositive and seronegative subjects. The only variables that differed were sex, age, smoking, C-reactive protein and physical activity index (Table 1) . Characteristics of the study population are shown in Supplementary Table 1 . The majority of the represented variables differed significantly between men and women, the only variables not deviating were age, education, insulin level and physical activity index (Supplementary Table 1 ). The characterization of these variables have been described elsewhere. 26 We were unable to find any host genetic polymorphisms associated with susceptibility to CMV infection, as none of the analyzed single nucleotide polymorphisms (SNPs) reached genome-wide levels of statistical significance (Po5 Â 10 ). However, under the dominant model, P-values showed slight departure from the expected null distribution (Figure 1b) . A total of 10 independent loci showed a suggestive association (Po1 Â 10
À5
) with CMV IgG titer in this model ( Table 2 ). The most significant SNP (rs17170316, P ¼ 8.42 Â 10
À7
) have no known function. The most significant signal carrying known function was identified on chromosome 15 in the AGBL1 (ATP/GTP binding like 1) gene with a lead SNP reaching P-value of 1.86 Â 10 À6 (Figure 2b ).
Discussion
In this study, we describe the first GWAS that evaluates the association of host genetic polymorphisms with CMV infection. The main result is that no strong evidence supported a role of host genetic components in the susceptibility to or the strength of anti-CMV IgG response in this study cohort. However, an examination of the polymorphisms associated with the strength of anti-CMV IgG response resulted in an interesting suggestive association for five SNPs (most significant P-value 1.86 Â 10
À6
) located in the AGBL1 gene, on 
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T Kuparinen et al in HIV-infected individuals. 23 CMV contains a human IL-10 homolog gene and utilizes it to evade host immune system. Sezgin et al. 23 performed a candidate gene approach by focusing on the polymorphisms in the IL-10R1 and IL-10 genes on the development of CMV retinitis in patients with AIDS. Their results suggest that in European Americans, one haplotype carrying an amino acid changing variation in the cytoplasmic domain of IL-10R1 can be protective against and other haplotype carrying an amino acid changing variation in the extracellular domain of IL-10R1 susceptible to CMV retinitis.
The population cohort used in this study represents healthy individuals, that is, the data consist of individuals without clinical disorders or other well-known CMV risk factors. An earlier study 22 from this laboratory investigated polymorphisms in the cytokine genes in healthy blood donors and found that frequencies of the tumor necrosis factor and the IL1RN alleles were slightly different in the seronegative individuals compared with the seropositive samples, suggesting that the alleles of these cytokines, which are known to be associated with a strong inflammatory reaction, may have a protective role against CMV infection. The authors of the study concluded that host genetics may have an impact on susceptibility to CMV infection, but the observed genetic effect was relatively weak, suggesting that environmental factors may have a decisive role.
It is likely that a high CMV antibody level results from either frequent viral reactivation or infection by a new strain. 30 It has been reported that high anti-CMV IgG titer level is associated with several pathological processes, including cardiovascular disease, 31, 32 cognitive decline in elderly individuals 10, 33 and even stress in healthy individuals. 34 However, the genetic basis of the strength of antibody response to CMV infection has not received much attention in CMV studies. If high anti-CMV IgG titer results from viral reactivations, it is possible that environmental CMV risk factors such as stress, which defuse the infection and induce the production of antibodies, are more important to the strength of anti-CMV IgG response than host genetic factors.
Although this GWAS did not reveal strong genetic components affecting the strength of anti-CMV IgG response, five suggestive signals implicated that the AGBLI gene may be related to CMV infection. The AGBL1 gene may have a role in the processing tubulin, by catalyzing the deglutamylation of polyglutamate side chains. The potential role of AGBL1 and tubulin in CMV infection could be explained in at least two ways. First, the microtubule network has been shown to have an important role in nuclear targeting of the CMV capsid in endothelial cells. It has been reported that CMV capsids associate with the microtubule network to facilitate movement to the nucleus before the onset of efficient CMV immediate-early gene expression. 35 Second, it has been shown that CMV remains quiescent in monocytes until the cells have differentiated into macrophages. During the late stages of replication in macrophages, the infectious virus accumulates in discrete cytoplasmic vacuoles where it can evade entry into the endosomallysomal system. It is currently unclear how the virus-containing vacuoles evade lysomal fusion, but it has been hypothesized that disaggregation of the microtubule network may have a role in the process. 36 Although CMV uses the microtubule network for movement and targeting, the link between these processes and the high anti-CMV IgG response to CMV infection is unclear. Researchers have hypothesized that CMVinduced disruption alters the trafficking of proteins involved in antigen-presenting pathways and that an inability to present antigens would prevent detection by the immune system. 36 We also represented the characteristics of seropositive and seronegative subjects and found that the only variables that differed between subjects were sex, age, smoking, C-reactive protein and physical activity index. These data are in accordance with previous reports. [37] [38] [39] This study has some limitations. CMV exists as either a productive, persistent infection or as a latent, nonproductive infection with periodic reactivation. 40 The duration of a persistent CMV infection cannot be determined by measuring anti-CMV IgG titer, and it is obvious that the cohort contained individuals with Host genetics in CMV infection T Kuparinen et al persistent infections. Thus, the present analysis might not detect possible genetic differences between these two terms of infection. In addition to this, the regulation of cellular anti-CMV immunity (T-cells and natural killer cells) remained (for obvious technical difficulties) uncharacterized.
In conclusion, our data fail to demonstrate any strong evidence for the importance of host genetics to susceptibility or the strength of antibody response to CMV infection. However, the data do suggest a role for the host AGBL1 gene in the strength of antibody response to CMV infection, a finding that merits further investigation.
Materials and methods

Study population
The Cardiovascular Risk in Young Finns Study is an ongoing, multi-center, follow-up study of the precursors to atherosclerosis in Finnish children and young adults. The first study was conducted in 1980, with 3596 randomly chosen participants from the national population registers of Helsinki, Tampere, Turku, Oulu, Kuopio, who were 3, 6, 9, 12, 15 or 18 years of age. The design of that study has been described elsewhere. 27, 41, 42 A follow-up of 2283 individuals, upon which the data of this study are based, was carried out in 2001, when the participants reached age of 24-39 years. Local Ethics Committees approved the study, and it was conducted following the guidelines of the Declaration of Helsinki. All subjects gave their written informed consent.
CMV serology
Anti-CMV IgG titer was measured in stored (À70 1C) baseline serum, originally obtained in year 2001 for the Cardiovascular Young Finns Study, using a commercial enzyme-linked immunosorbent assay kit (Enzygnost Anti-CMV/IgG, Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany). Seropositivity for CMV was defined as a serum anti-CMV IgG titer of X230, according to the manufacturer's instructions. This analysis found 1486 seropositive and 648 seronegative individuals.
DNA extractions
Blood samples were drawn into tubes containing EDTA and were stored at À70 1C. DNA was extracted from peripheral blood leukocytes using a commercially available kit and the BioRobot M48 Workstation (Qiagen Inc., Hilden, Germany), according to the manufacturer's instructions.
Genotyping and quality control
In this study, genome-wide SNP genotyping was done using a custom Illumina BeadChip (Illumina, Inc., San Diego, CA, USA) containing in total 670 000 SNPs and copy-number variant probes from 2442 participants (1123 males, 1319 females). The custom 670 K chip shares 562 643 SNPs in common with the Illumina Human610 BeadChip. Genotypes were called using clustering algorithm Illuminus. 43 A total of 2556 samples were genotyped. After initial clustering, we removed two subjects with poor call rates (CR o0.90), and an additional 54 samples failed subsequent quality control because of being duplicated samples, heterozygosity, a 44 There were 51 pairs of individuals with pi-hat (proportion of identity-by-descent) 40.2, and these individuals were thus removed because of their possible relatedness. One member of the pair was removed using greater missingness as a criterion. After a final check of frequency and genotyping, there were 546 677 SNPs available from 2442 subjects. Genotype imputation was performed for the SNP data using MACH 45 with the HapMap phase II (release 22 CEU, NCBI build 36, dbSNP 126) haplotypes as a reference.
Statistical analyses
Rank-based inverse normal transformation was applied to individual serum anti-CMV IgG titers to account for the non-normal distribution of titer levels and to make the results of the study more robust. Four significant covariates, age, sex, high-density lipoprotein cholesterol and the geographical area of the subcohorts (Helsinki, Tampere, Turku, Oulu and Kuopio, see cohort description), were used to adjust the transformed titer values using a multivariate linear regression model. The transformed titer levels were also adjusted for one significant principal component (analyzed using genotyping information). 46 Residuals were standardized (mean ¼ 0, s.d. ¼ 1), and their distribution was confirmed to be very close to normal by visual quantile-quantile (Q-Q) plot analysis (Figure 1) .
To examine the strength of antibody response to CMV infection, tests for additive, recessive and dominant genetic effects were carried out on a linear scale using linear regression (anti-CMV IgG titer level). Analyses contained individuals with both negative (defined as o230) and positive (X230) titers. A logistic regression including both an additive and a dominant model was used to identify polymorphisms associated with susceptibility to infection (seropositivity versus seronegativity). The significant covariates used in adjustments were age, sex, smoking and the geographical area of the subcohorts. Genotypes were coded as 0, 1 or 2 when the SNP was genotyped and by dosage (scale 0-2) when imputed. These tests were performed to assess the association of SNPs with the standardized residuals using PLINK 44 for the genotyped data. ProbABEL 47 was used to fit the model, considering the genotype uncertainty in imputed SNPs. P-values were combined from the analysis by favoring genotyped SNPs over imputed ones. The Manhattan plots (Figure 2a and Supplementary  Figure 1) were drawn for analysis of results. The P-value for genome-wide significance was set at Po5 Â 10
À8
,
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T Kuparinen et al corresponding to a target a of 0.05 with a Bonferroni correction for 1 million independent tests. Comparisons of the variables between sexes and CMVseropositive and CMV seronegative-participants were performed with the Student's t-test, Mann-Whitney test and w 2 test using SPPS version 19.0 (SPSS Inc., Chicago, IL, USA). The level of Po0.05 was considered statistically significant.
GWAS power calculation
All associations of dichotomous CMV titer with SNPs, their accompanying odds ratio and confidence intervals were evaluated by the additive logistic regression model. The study was powered to detect CMV titer genetic relative risks of 1.37 at the genome-wide significance level with a power of 95% for SNPs with a minor allele frequency of 40.1 and for relative risks of 1.33 with a power of 80% when assuming 70% prevalence for the positive CMV titer. We had over 80% power to detect an effect size of 2% heritability with the dominant genetic model for continuous inverse normal transformed CMV titer. We used PGA program 48 for dichotomous CMV titer and QUANTO 1. 
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